What have we learnt about the development and progression of early RA from RCTs?

Best Practice and Research: Clinical Rheumatology

Volumn 23, Issue 1, 2009, Pages 13-24

  Scott, David L ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

DMARD; early rheumatoid arthritis; placebo controlled trial; randomized controlled trial

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; BECLOMETASONE; CHLOROQUINE; CYCLOSPORIN; CYCLOSPORIN A; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLD DERIVATIVE; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

BONE EROSION; CLINICAL PROTOCOL; CLINICAL STUDY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EARLY INTERVENTION; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; INTERVENTION STUDY; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; THERAPY DELAY;

ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 60449085696     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2008.12.009     Document Type: Review

References (64)

1. Dwosh I.L., Stein H.B., Urowitz M.B., et al. Azathioprine in early rheumatoid arthritis. Comparison with gold and chloroquine. Arthritis Rheum 20 (1977) 685-692
2. Mäkisara P., Nissilä M., Kajander A., et al. Comparison of penicillamine and gold treatment in early rheumatoid arthritis. Scand J Rheumatol 7 (1978) 166-170
3. Quinn M.A., Conaghan P.G., and Emery P. The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence?. Rheumatology 40 (2001) 1211-1220
4. Choy E.H., Smith C., Doré C.J., and Scott D.L. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology 44 (2005) 1414-1421
5. Quinn M.A., and Cox S. The evidence for early intervention. Rheum Dis Clin North Am. 31 (2005) 575-589
6. Finckh A., Liang M.H., van Herckenrode C.M., and de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 55 (2006) 864-872
7. Combe B., Landewe R., Lukas C., et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66 (2007) 34-45
8. Meyer O., de Bandt M., Berthelot J.M., et al., Working Group for Therapeutic Strategies for Rheumatoid Arthritis. Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' first-line DMARD therapy. Joint Bone Spine 74 (2007) 73-78
9. Kirwan J.R., Bijlsma J.W., Boers M., and Shea B.J. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 1 (2007) CD006356
10. Du Pan S.M., Gabay C., and Finckh A. A systematic review of infliximab in the treatment of early rheumatoid arthritis. Ther Clin Risk Manag 3 (2007) 905-911
11. Donahue K.E., Gartlehner G., Jonas D.E., et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 148 (2008) 124-134
12. Borg G., Allander E., Lund B., et al. Auranofin improves outcome in early rheumatoid arthritis. Results from a 2 year double-blind, placebo controlled study. J Rheumatol 15 (1988) 1747-1754
13. The Australian Multicentre Clinical Trial Group. Sulfasalazine in early RA. J Rheumatol 19 (1992) 1672-1677
14. Hannonen P., Mottenen T., Hakola M., and Oka M. Sulfasalazine in early rheumatoid arthritis. A 48 week double-blind, prospective, placebo-controlled study. Arthritis Rheum 36 (1993) 1501-1509
15. Choy E.H., Scott D.L., Kingsley G.H., et al. Treating rheumatoid arthritis early with disease modifying drugs reduces joint damage: a randomised double blind trial of sulphasalazine vs diclofenac sodium. Clin Exp Rheumatol 20 (2002) 351-358
16. Davis M.J., Dawes P.T., Fowler P.D., et al. Should disease modifying drugs be used in mild rheumatoid arthritis?. Br J Rheumatol 30 (1991) 451-454
17. Clark P., Casas E., Tugwell P., et al. Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial. Ann Intern Med 119 (1993) 1067-1071
18. The HERA study group. A randomised trial of hydroxychloroquine in early rheumatoid arthritis: The HERA study. Am J Med 98 (1995) 156-168
19. van Everdingen A.A., Jacobs J.W., Siewertsz Van Reesema D.R., and Bijlsma J.W. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 136 (2002) 1-12
20. Jacobs J.W., van Everdingen A.A., Verstappen S.M., and Bijlsma J.W. Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo. Arthritis Rheum 54 (2006) 1422-1428
21. Stein C.M., and Pincus T. Placebo-controlled studies in rheumatoid arthritis: ethical issues. Lancet 353 (1999) 400-403
22. Buckland-Wright J.C., Clarke G.S., Chikanza I.C., and Grahame R. Quantitative microfocal radiography detects changes in erosion area in patients with early rheumatoid arthritis treated with myocrisine. J Rheumatol 20 (1993) 243-247
23. Egsmose C., Lund B., Borg G., et al. Patients with early arthritis benefit from early 2nd line therapy: 5 year follow-up of a prospective double blind placebo controlled study. J Rheumatol 22 (1995) 2208-2213
24. Van der Heide A., Jacobs J.W.G., Bijlsma J.W.J., et al. The effectiveness of early treatment with 'second-line' anti-rheumatic drugs. A randomized controlled trial. Ann Intern Med 124 (1996) 699-707
25. Munro R., Hampson R., McEntergart A., et al. Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study. Ann Rheum Dis 57 (1998) 88-93
26. Lard L.R., Visser H., Speyer I., et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 111 6 (2001 Oct 15) 446-451
27. Verstappen S.M., Jacobs J.W., Bijlsma J.W., et al., Utrecht Arthritis Cohort Study Group. Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year. Arthritis Rheum 48 (2003) 1797-1807
28. Nuver-Zwart I.H., Van Riel P.L.C.M., Van de Putte L.B.A., and Gribnau F.W.J. A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine. Ann Rheum Dis 48 (1989) 389-395
29. Van der Heijde D.M., Van Riel P.L., Nuver-Zwart I.H., et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1 (1989) 1036-1038
30. Peltomaa R., Paimela L., Helve T., and Leirisalo-Repo M. Comparison of intramuscular gold and sulphasalazine in the treatment of early rheumatoid arthritis. A one year prospective study. Scand J Rheumatol 24 (1995) 330-335
31. Menninger H., Herborn G., Sander O., et al. A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis. Br J Rheumatol 37 (1998) 1060-1068
32. Rau R., Herborn G., Karger T., et al. Progression in early erosive rheumatoid arthritis: 12 month results from a randomised controlled trial comparing methotrexate and gold sodium thiomalate. Br J Rheumatol 37 (1998) 1220-1226
33. Zeidler H.K., Kvien T.K., Hannonen P., et al. Progression of joint damage in early active severe rheumatoid arthritis during eighteen months of treatment: comparison of low dose cyclosporin and parenteral gold. Br J Rheumatol 37 (1998) 874-882
34. Stenger A.A.M.E., Van Leuewen M.A., Houtman P.M., et al. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol 37 (1998) 1157-1163
35. Van Jaarsveld C.H.M., Jacobs J.W.G., van der Veen M.J., et al. Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. Ann Rheum Dis 59 (2000) 468-477
36. Verstappen S.M., Jacobs J.W., van der Veen M.J., et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 66 (2007) 1443-1449
37. Haagsma C., van Riel P., de Jong A.J., et al. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 36 (1997) 1082-1088
38. Dougados M., Combe B., Cantagrel A., et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 58 (1999) 220-225
39. Gerards A.H., Landewe R.B., Prins A.P., et al. Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis. Ann Rheum Dis 62 (2003) 291-296
40. Marchesoni A., Battafarano N., Arreghini M., et al. Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatology 42 (2003) 1545-1549
41. Miranda J.M., Alvarez-Nemegyei J., Saavedra M.A., et al. (GRECIA Group). A randomized, double-blind, multicenter, controlled clinical trial of cyclosporine plus chloroquine vs. cyclosporine plus placebo in early-onset rheumatoid arthritis. Arch Med Res 35 (2004) 36-42
42. Sarzi-Puttini P., D'Ingianna E., Fumagalli M., et al. An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis. Rheumatol Int 25 (2005) 15-22
43. Kirwan J.R. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 333 (1995) 142-146
44. Proudman S.M., Conaghan P.G., Richardson C., et al. Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 43 (2000) 1809-1819
45. Capell H.A., Madhok R., Hunter J.A., et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis 63 (2004) 797-803
46. Svensson B., Boonen A., Albertsson K., et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 52 (2005) 3360-3370
47. Wassenberg S., Rau R., Steinfeld P., and Zeidler H. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years. Arthritis Rheum 52 (2005) 3371-3380
48. Hetland M.L., Stengaard-Pedersen K., Junker P., et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis. Arthritis Rheum 54 (2006) 1401-1409
49. Breedveld F.C., Emery P., Keystone E., et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 63 (2004) 149-155
50. St Clair E.W., van der Heijde D.M., Smolen J.S., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50 (2004) 3432-3443
51. Taylor P.C., Steuer A., Gruber J., et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum 50 (2004) 1107-1116
52. Quinn M.A., Conaghan P.G., O'Connor P.J., et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal. Arthritis Rheum 52 (2005) 27-35
53. Breedveld F.C., Weisman M.H., Kavanaugh A.F., et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 (2006) 26-37
54. Emery P., Breedveld F.C., Hall S., et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372 (2008) 375-382
55. Boers M., Verhoeven A.C., Markusse H.M., et al. Randomised comparison of combined step-down prednisolone, methotrexate and suphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350 (1997) 309-318
56. Mottonen T., Hannonen P., Leirisalo-Repo M., et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 353 (1999) 1568-1573
57. Choy E.H., Smith C.M., Farewell V., et al., CARDERA (Combination Anti-Rheumatic Drugs in Early Rheumatoid Arhritis) Trial Group. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis 67 (2008) 656-663
58. van den Borne B.E., Landewe R.B., Goei The H.S., et al. Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine. J Rheumatol 25 (1998) 1493-1498
59. Ferraccioli G.F., Gremese E., Tomietto P., et al. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A,sulphasalazine) or monotherapy for three years. Rheumatology 41 (2002) 892-898
60. Grigor C., Capell H., Stirling A., et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364 (2004) 263-269
61. Capell H.A., Madhok R., Porter D.R., et al. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis 66 (2007) 235-241
62. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 146 (2007) 406-415
63. Saunders S.A., Capell H.A., Stirling A., et al. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum 58 (2008) 1310-1317
64. van Tuyl L.H., Lems W.F., Voskuyl A.E., et al. Tight control and intensified COBRA combination therapy in early rheumatoid arthritis: 90% remission in a pilot trial. Ann Rheum Dis 67 (2008) 1574-1577